Dynavax Technologies Corp (NASDAQ:DVAX)
CAPS Rating:
A biopharmaceutical company that discovers and develops Toll-like Receptor 9 and agonist-based products to treat and prevent infectious diseases, allergies, cancer and chronic inflammatory.
RSS Headlines
Fool UK
Recs
this has several studies in the pipeline, they have to re visit the FDA panel, but they rated 8-5, they will get the approval and this stock will get the big cap investors back.